Low Strength IDP-107
DrugOnce a day for 12 weeks
NCT Number: NCT00666900
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
Looking for future studies?
Notify Me12 year and older
All sexes
Interventional
Phase 2
Burke Pharmaceutical Research, Hot Springs, Arkansas, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once a day for 12 weeks
Once a day for 12 weeks
Once a day for 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 12 weeks
Looking for future studies?
Notify MeDow Pharmaceutical Sciences
Industry
A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07384208
Acne Vulgaris, Acneiform Eruptions
Bologna, Italy
View Trial DetailsNCT07384195
Acne Vulgaris, Acneiform Eruptions
Ancona, AN, Italy
View Trial DetailsNCT03334682
Acne Vulgaris, Acneiform Eruptions
Brest, France
View Trial DetailsNCT07753811
Acne Vulgaris, Acneiform Eruptions
Banhā, Egypt
View Trial Details